ConductScience.org, home

Paper1680554

On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans.

Liliemark J and 1 other. Cancer Res, 1991. Cited by 107 papers, by iCite.

Cite this record

ConductScience Library. On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. Papers, record 1680554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1680554

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans.
PubMed
Journal
Cancer Res
PubMed
Year
1991
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
107
iCite
Relative citation ratio, by iCite
3.44
iCite
Revised in PubMed
2013-11-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liliemark JJ
2Juliusson GG

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
2-ChloroadenosineMajor topic
DeoxyadenosinesMajor topic
Chromatography, High Pressure Liquid
Cladribine
Humans
Leukemia

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.

PMIDTitleJournalYearIn PapersSource
33976256IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.Sci Rep2021https://conductscience.org/library/papers/33976256PubMed
253862492-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma.Dermatol Reports2010https://conductscience.org/library/papers/25386249PubMed
21679466Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.BMC Cancer2011https://conductscience.org/library/papers/21679466PubMed
20957121Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.Neuropsychiatr Dis Treat2010https://conductscience.org/library/papers/20957121PubMed
19325518Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.Molecules2009https://conductscience.org/library/papers/19325518PubMed
16363884Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.Drugs Aging2005https://conductscience.org/library/papers/16363884PubMed
15757511Application of population pharmacokinetics to cladribine.BMC Pharmacol2005https://conductscience.org/library/papers/15757511PubMed
9068927The clinical pharmacokinetics of cladribine.Clin Pharmacokinet1997https://conductscience.org/library/papers/9068927PubMed
8751045Kinetics and metabolism of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in the isolated perfused rat liver.Eur J Drug Metab Pharmacokinet1995https://conductscience.org/library/papers/8751045PubMed
8617573Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro.Invest New Drugs1995https://conductscience.org/library/papers/8617573PubMed
8137458Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8137458PubMed
8104793On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole.Eur J Clin Pharmacol1993https://conductscience.org/library/papers/8104793PubMed
80940032'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.Br J Cancer1993https://conductscience.org/library/papers/8094003PubMed
7995327Protein binding of 2-chloro 2'-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemia.Eur J Clin Pharmacol1994https://conductscience.org/library/papers/7995327PubMed
7948311Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.Ann Hematol1994https://conductscience.org/library/papers/7948311PubMed
7905693Successful prevention of neurological deficit in SAH patients with 2-chlorodeoxyadenosine.Acta Neurochir (Wien)1993https://conductscience.org/library/papers/7905693PubMed
7850921A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7850921PubMed
7554045Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7554045PubMed
7507037Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.Drugs1993https://conductscience.org/library/papers/7507037PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1680554

GET https://conductscience.org/api/papers/v1/1680554/authors